A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
||Gilead Sciences, Inc
||Male and Female Patients
||Theresa Lukose: 212-305-6758 / email@example.com
This study will compare two experimental drugs, named Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination (SOF/VEL/GS-9857 FDC) and Sofosbuvir/Velpatasvir (SOF/VEL) FDC for the treatment ofchronic genotype 3 hepatitis C virus (HCV) infection in patients who have cirrhosis, or scarring of the liver. The purpose of this study is to determine the efficacy, safety, and tolerability of SOF/VEL/GS-9857 in comparison to SOF/VEL in patients infected with chronic genotype 3 HCV infection and cirrhosis. Information about any side effects that may occur will also be collected.
This study is closed
Elizabeth Verna, MD
|Have you been diagnosed with Chronic HCV Infection and Cirrhosis?